ORYN-1001

N/A

Report date: 2024/01/03 15:05:26
NME

Base Information

Drug NameORYN-1001
Drug Alias NameORTDORTD-1ORYN-1001
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionDisintegrin and metalloproteinase domain-containing protein 17 inhibitorsNuclear factor NF-kappa-B complex inhibitors
TargetsDisintegrin and metalloproteinase domain-containing protein 17Nuclear factor NF-kappa-B complex
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Arthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOryn Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesOryn Therapeutics Llc
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A